Therapeutic efficacy of imatinib mesilate (glivec) in a chronic phase of myeloid leukemia

Terapevticheskii Arkhiv

Volumn 75, Issue 8, 2003, Pages 62-67

  Turkina, A G ^a   Khoroshko, N D ^a   Druzhkova, G A ^a   Zingerman, B V ^a   Zakharova, E S ^a   Chelysheva, E Yu ^a   Vinogradova, O Yu ^a   Domracheva, E V ^a   Zakharova, A V ^a   Kovaleva, L G ^a   Kolosheinova, T I ^a   Kolosova, L Yu ^a   Zhuravleva, V S ^a   Tikhonova, L Yu ^a  

^a NONE

Author keywords

Chronic myeloid leukemia; Cytogenetic response; Glivec; Imatinib mesilate; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CHROMOSOME ANALYSIS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; HUMAN; KARYOTYPING; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MYELOID LEUKEMIA; REMISSION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CYTOGENETIC ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION;

EID: 1542495243     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukemia giemsa starting. Nature 1973; 243: 290-303.
2. Gordon M. Y. Cellular and molecular mechanisms in chronic myeloid leukemia: biology and treatment. Br. J. Haematol. 1996; 95: 10-20.
3. Druker B. J., Lydon N. B. Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myeloid leukemia. J. Clin. Invest. 2000; 105: 3-7.
4. Deininger M. V., Goldman G. J., Lydon N., Melo J. V. The tyrosine kinase inhibitor CGP571148 B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90: 3691-3698.
5. Kantarjian H. M., O'Brien S., Anderini P., Talpaz M. Treatment of chronic myelogenous leukemia: current status and investigation options. J. Am. Soc. Hematol. 1996; 87 (8): 3069-3080.
6. Allan N. C., Richards S. M., Sheperd P. C. A et al. UK Medical Research Council randomised multicentre trial of interferon-α in chronic myeloid leukaemia: improved servival irrespective of cytogenetic response. Lancet 1995; 345: 1392-1397.
7. Kantarjian H. M., Francis J., O'Brien S., Talpaz M. Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and hemotherapy. Hematol./Oncol. Clin. N. Am. 1998; 12 (1): 31-79.
8. Druker B. J., Talpaz M., Debra J. et al. Efficacy and safety of specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl. J. Med. 2001; 344 (14): 1031-1037.
9. Kantarjian H., Sawyers C. L., Hochhaus A. et al. Phase II study of STI571 in patients with resistance or refractory Philadelphia chromosome positive chronic myeloid leukemia. Blood 2000; 96: 470a.
10. Talpaz M., Kautarjian H. M., McCredie K. B. et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N. Engl. J. Med. 1986; 314: 1065-1069.
11. Pinkel D., Straume T., Gray Y. W., Proc. Natl. Acad. Sci., USA 1986; 2934-2938.
12. Kobzev Y. N., Domracheva E. V., Zakharova A. V. et al. Cancer Genet. Cytogenet. 1998; 106: 128-134.
13. Kantarjian H. M., Smith T. L., McCredic K. B. et al. Chronic myelogenous leukemia: a multivariate analysis of the association patient characteristics and therapy with survival. Blood 1985; 66: 1326-1335.
14. Talpaz V., Silver R. T., Druker B. J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99 (6): 1928-1937.
15. Kantarjian H. M., O'Brien S., Cortes J. Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML AP) with imatinib mesilate (STI571). In: Hematology. Orlando, Florida; 2001; abstr. 594.
16. Druker B. J., Charles L., Saviers C. L. Activity of specific inhibitor of BCR-ABL tyrosin kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 2001; 344: 1038-1042.
17. Larson R. On behaf of IRIS Imatinib (STI571 Glivec) as initial therapy for patients with newly Ph+ chronic myelod leukemia (CML): results of a randomized phase III study vs interferon +Ara-C in). Blood 2002; 100 (11): 48.